STAT3 polymorphism: a potential marker of response to IFN-
therapy in metastatic RCC
This article has no abstract so we have provided the first paragraph of the full text.
Interferon (IFN)-
immunotherapy has been used in patients with metastatic renal cell carcinoma (MRCC), as conventional chemotherapy is ineffective in this setting. Rates of response to IFN- immunotherapy are, however, low and there is a need for markers to predict which patients will benefit from this treatment. In order to identify such a marker, Ito and colleagues carried out a comprehensive association study in a population of Japanese patients who had been treated with IFN- for MRCC.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.